Vertex Pharmaceuticals Incorporated (VRTX) Q3 2012 Earnings Results

Vertex Pharmaceuticals Misses on EPS — Stock Up 4.56%

Despite missing EPS expectations, Vertex Pharmaceuticals' stock rose by 4.56%, indicating investor optimism. The increase may be attributed to positive sentiment around their ongoing drug development efforts. Investors seem to be looking beyond the short-term EPS miss, focusing instead on the company's long-term potential.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.13	N/A	-32.64%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains focused on advancing their drug development programs. They acknowledged the EPS shortfall but emphasized their commitment to future growth.

Management highlighted ongoing developments in their pipeline.

They expressed confidence in long-term growth despite the EPS miss.

Vertex Pharmaceuticals Misses on EPS — Stock Up 4.56%

Key numbers

Management commentary

Vertex Pharmaceuticals Incorporated

More earnings this week

Vertex Pharmaceuticals Misses on EPS — Stock Up 4.56%

Key numbers

Management commentary